| Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers |
The addition of a seasoned VP of Marketing compliments the recent hiring of the Company's VP of Sales to establish its commercialization readiness infrastructure |
globenewswire.com |
2025-04-23 12:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System |
Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY ® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting. |
globenewswire.com |
2025-04-09 12:30:00 |
Czytaj oryginał (ang.) |
| REMINDER: Microbot Medical Announces Data from the Company's ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting |
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter |
globenewswire.com |
2025-04-01 12:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System |
Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year |
globenewswire.com |
2025-03-04 10:30:00 |
Czytaj oryginał (ang.) |
| Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting |
BRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone. |
globenewswire.com |
2025-02-25 10:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Closes $13 Million Registered Direct Offering |
BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 6,103,289 shares of the Company's common stock at a purchase price of $2.13 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series I preferred investment options. The short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock have an exercise price of $2.13 per share and will be exercisable for a period of two years beginning on the later of (i) the effective date of the increase of the Company's authorized shares of common stock following stockholder approval and (ii) the effective date of stockholder approval of the issuance of the series I preferred investment options and the shares issuable upon exercise thereof. |
globenewswire.com |
2025-02-11 20:15:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules |
BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of the Company's common stock at a purchase price of $2.13 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series I preferred investment options. The short-term series I preferred investment options to purchase up to 12,206,578 shares of common stock have an exercise price of $2.13 per share and will be exercisable for a period of two years beginning on the later of (i) the effective date of the increase of the Company's authorized shares of common stock following stockholder approval and (ii) the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about February 11, 2025, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2025-02-10 10:00:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Closes $8.6 Million Registered Direct Offering |
BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company's common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter. |
globenewswire.com |
2025-01-10 12:25:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility |
HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 4,000,001 shares of the Company's common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered short-term series G preferred investment options. The short-term series G preferred investment options to purchase up to 8,000,002 shares of common stock have an exercise price of $1.75 per share and are immediately exercisable following issuance for a period of two years thereafter. |
globenewswire.com |
2025-01-07 18:15:00 |
Czytaj oryginał (ang.) |
| Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY® |
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 |
globenewswire.com |
2024-12-30 10:30:00 |
Czytaj oryginał (ang.) |
| MBOT Stock Gains Following FDA Submission of the LIBERTY System |
Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance. |
zacks.com |
2024-12-12 14:56:08 |
Czytaj oryginał (ang.) |
| Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access |
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live |
globenewswire.com |
2024-12-10 12:18:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Stock Rises After Completing ACCESS-PVI Trial |
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission. |
zacks.com |
2024-10-16 17:25:16 |
Czytaj oryginał (ang.) |
| Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025 |
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully completed enrollment and follow up for all patients in its ACCESS-PVI human clinical trial. |
globenewswire.com |
2024-10-15 12:38:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up |
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it is currently experiencing an acceleration of patient enrollment for ACCESS-PVI human clinical trial for LIBERTY®. |
globenewswire.com |
2024-09-30 12:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System |
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 |
globenewswire.com |
2024-09-17 12:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY |
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY. |
zacks.com |
2024-08-23 17:01:50 |
Czytaj oryginał (ang.) |
| Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System |
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform |
globenewswire.com |
2024-08-22 12:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical (MBOT) Gets Quality Certification for its System |
Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization. |
zacks.com |
2024-08-19 16:05:22 |
Czytaj oryginał (ang.) |
| Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization |
The ISO 13485 certification is a validation of the Company's robust quality system The ISO 13485 certification is a validation of the Company's robust quality system |
globenewswire.com |
2024-08-13 12:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics |
Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system. |
zacks.com |
2024-08-05 16:30:39 |
Czytaj oryginał (ang.) |
| Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System |
The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system |
globenewswire.com |
2024-08-01 12:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center |
As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women's Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women's Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trial |
globenewswire.com |
2024-07-18 12:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical (MBOT) Progresses in Its Human Clinical Trial |
Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system. |
zacks.com |
2024-07-11 18:51:05 |
Czytaj oryginał (ang.) |
| Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial |
Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company's Pivotal Human Clinical Trial. |
globenewswire.com |
2024-07-09 12:30:00 |
Czytaj oryginał (ang.) |
| Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial |
The first clinical case was performed at Brigham and Women's Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular Robotic Surgical System BRAINTREE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the completion of the first procedure in a patient utilizing its LIBERTY® Endovascular Robotic Surgical System. |
globenewswire.com |
2024-07-08 12:20:00 |
Czytaj oryginał (ang.) |
| Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial |
Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures. |
zacks.com |
2024-07-05 16:51:01 |
Czytaj oryginał (ang.) |
| Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY |
Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption. |
zacks.com |
2024-07-04 18:50:56 |
Czytaj oryginał (ang.) |
| Microbot Medical Partners with Baptist Hospital of Miami to Participate in its Pivotal Human Clinical Trial |
Following the Company's recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial Following the Company's recent FDA approval to commence its pivotal human clinical trial, Baptist Hospital of Miami is the second clinical site to enroll in the trial |
globenewswire.com |
2024-07-03 12:20:00 |
Czytaj oryginał (ang.) |